The study will include up to 1,420 participants ages 18-55 across three cohorts, according to a news release.
The first cohort includes 615 participants who received two doses of Pfizer’s original COVID-19 vaccine 90-180 days prior to enrollment. They will receive one or two doses of the omicron-specific vaccine.
The second cohort includes 600 participants who received three doses of Pfizer’s original COVID-19 vaccine 90-180 days prior to enrollment. They will receive one dose of the original vaccine or the omicron-specific vaccine.
The third cohort includes 205 unvaccinated participants. They will receive three doses of the omicron-specific vaccine.
Read Pfizer’s release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
